Skip to main navigation

Monte Rosa

4634 M

45°56′12.6″N

07°52′01.4″E

Approach
QuEEN / Pipeline
Our Team
Careers
Newsroom
Media / Investors

INVESTORS

Events & Presentations

Photo a person pointing on a computer screen

Investors

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
- Stock Quote & Chart
Analyst Coverage
Corporate Governance
Financials & Filings
- SEC Filings
IR Resources

Corporate Presentation

Monte Rosa Corporate Presentation – August 2024

Presentations

6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader 2.8 MB

Trends in Immunology - VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases 1.2 MB

EULAR 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model 3.1 MB

DDW 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression 1.2 MB

AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer 1.9 MB

Molecular Glue Drug Development Summit January 2024 – Accelerating Molecular Glue Discovery Through AI/ML & Computation 8.6 MB

Keystone Symposia January 2024 – Teaching CRBN New Tricks 6.3 MB

ACR 2023 – A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model 8.5 MB

Monte Rosa Company Call Presentation - October 17 2023 1.8 MB

AACR 2023 - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers 4.4 MB

AACR 2023 - Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction 4.3 MB

MRT-2359 KOL Webinar, October 24, 2022 4.5 MB

34th EORTC-NCI-AACR Symposium 4.1 MB

5th Annual TPD Summit - Preclinical and Mechanism of Action Studies of MRT-2359 5.1 MB

5th Annual TPD Summit - AI Applications for Molecular Glue Degraders 9.2 MB

American Association for Cancer Research Annual Meeting, April 8-13, 2022 1 MB

2nd Annual TPD Europe Summit Presentation 3.9 MB

4th Annual Targeted Protein Degradation Summit Presentation 4.8 MB

AACR-NCI-EORTC Late Breaking Presentation 2.1 MB

European Protein Degradation Congress 2021 Presentation 3.8 MB

Upcoming Events

There are no upcoming events available at this time.

Recent Events

Wells Fargo 2024 Healthcare Conference

Sep 5, 2024 at 2:15 PM EDT

Click Here for Webcast

Past Events

UBS Targeted Protein Degradation Day

Jul 15, 2024 at 3:30 PM EDT

Click Here for Webcast

Jefferies Global Healthcare Conference

Jun 6, 2024 at 3:30 PM EDT

Click Here for Webcast

TD Cowen 44th Annual Health Care Conference - Breast & Lung Cancer Corporate Panel Discussion

Mar 6, 2024 at 9:10 AM EST

Click Here for Webcast

Guggenheim 6th Annual Biotechnology Conference

Feb 7, 2024 at 1:30 PM EST

Click Here for Webcast

J.P. Morgan 42nd Annual Healthcare Conference

Jan 10, 2024 at 3:00 PM PST

Click Here for Webcast

Piper Sandler 35th Annual Healthcare Conference

Nov 28, 2023 at 3:30 PM EST

Click Here for Webcast

TD Cowen 7th Annual Fall Oncology Innovation Summit

Nov 3, 2023 at 1:00 PM EDT

Click Here for Webcast

MRT-2359 Interim PK/PD and Clinical Data and Corporate Update

Oct 17, 2023 at 8:00 AM EDT

Click Here for Webcast

Supporting Materials

Monte Rosa Company Call Presentation - October 17 2023 1.8 MB

HEAD OFFICE / LAB

BOS

321 Harrison Avenue, Suite 900
Boston, MA 02118
United States
617-949-2643

OFFICE / LAB

BSL

Monte Rosa Therapeutics AG
WKL-136.3
Klybeckstrasse 191
4057 Basel, Switzerland

MONTE ROSA THERAPEUTICS ©2024

info@monterosatx.com

Privacy Policy Terms of Use